Objective: The aim of this study was to perform a systematic review and meta-analyses of observational studies of transcatheter aortic valve replacement (TAVR) for bicuspid aortic valve stenosis (BcAV).
| I N TR ODU C TI ON
The bicuspid aortic valve (BcAV) is the most common congenital cardiac anomaly described to date. The prevalence is estimated at 1% [1] . The BcAV is prone to the development of accelerated sclerosis and calcific degeneration. Clinical abnormalities include development of aortic stenosis and aortic regurgitation [2] . The bicuspid valve underlies the majority of aortic valve replacements in patients below the age of 60 [3] . Transcatheter aortic valve replacement (TAVR) became the therapy of choice for tricuspid aortic valve (TcAV) stenosis in selected patients [4, 5] . The question then arises:
what about TAVR for stenotic BcAV? Theoretical concerns included:
(1) Increased annular ellipticity and asymmetric calcification, with geometric mismatch between the ovoid annulus and circular prosthesis leading to paravalvular leaks or leaflet asymmetry [6] , and (2) questionable strength of the bicuspid annulus, with potential increase in the risk of annular rupture or aortic dissection [6] .
Patients with BcAV were therefore excluded from all randomized TAVR trials [7, 8] . The off label use of TAVR in the bicuspid population has been reported in several case series. Adverse signals related to increased paravalvular leak (PVL) [9] , valve malposition [10] , higher permanent pacemaker implantation (PPM) rates [11] were noted. Comparative excess mortality was seen in one series [12] .
The generalizability was limited by small sample sizes. We therefore performed a systematic review and meta-analyses of observational studies of TAVR for BcAV to increase sample size and statistical power.
| M E TH ODS
The preferred reporting items for systematic reviews and meta analyses statement was used as a guideline for reporting this metaanalysis [13] .
| Study objectives
The aim of this analysis was to evaluate the outcomes of TAVR in stenotic BcAV. Prespecified analyses were performed to evaluate two primary outcomes, which were the composites of device success and early safety as defined in the Valve Academic Research Consortium (VARC) 2 consensus document [14] . The individual components of the composite outcomes were defined as secondary outcomes. Comparison was then provided with historical and contemporary outcomes of TAVR in TcAV.
| Literature search
Utilizing the expertise of a professional medical librarian, we searched multiple medical databases (Medline, Embase, Central, PubMed, and Scopus) from each database's inception until September 30, 2016 for studies related to TAVR for BcAV published in English. We used both medical subject heading terms and plain text word searches. The detailed search strategy is listed in the Appendix.
| Selection criteria
We targeted studies of TAVR for BcAV in more than one patient with at least 1 month of outcome data. The initial search yielded 227 entries. Duplicates were removed. We reviewed the abstracts.
When abstracts were unavailable, the full text was retrieved. The majority were unrelated topics which were discarded. We also removed narrative reviews, systematic analyses, imaging studies, conference abstracts and single case reports. We compared cumulative publications from research groups looking for overlap. In case of multiple studies with complete overlap, the study with the largest sample size and complete outcome data was included in the analysis.
| Data abstraction
The primary authors (G.R. and Z.W.) performed the data abstraction and statistical analysis. All 13 studies were read in their entirety prior to data abstraction. Selected data items of interest were extracted into templated forms and were reviewed for accuracy. Outcomes were included if they corresponded to VARC 2 definitions. When study definitions differed from VARC 2 definitions, outcomes were recalculated using raw data from the studies. Mutual consensus was used to resolve disagreement regarding study definitions and outcome values. 
| Bias evaluation
We selected six items from the Newcastle-Ottawa Scale to evaluate the risk of study bias, including elements relating to selection (representativeness of subjects, ascertainment of exposure, absence of outcome) and outcomes (assessment of outcomes, length of follow-up, adequacy of follow-up).
| Clinical definitions
The VARC 2 definitions were used uniformly throughout this analysis.
Device success was defined as the composite of: (1) 
| Statistical analysis
We extracted or calculated the outcomes of interest (event rates) from the included studies. All analyses were prespecified. Confidence intervals were estimated using the exact binominal distribution [15] . We used the Freeman-Tukey Double Arcsine method [16] to normalize event rates and pooled estimates using the DerSimonian and Laird random-effects method [17] . Heterogeneity was evaluated using the I 2 indicator, in which I 2 > 50% with P < 0.1 shows substantial heterogeneity. We were unable to evaluate publication bias due to the small number of studies included in the analyses [18] . All statistical analyses were conducted using Stata version 14.2 (StataCorp LP, College Station, TX).
| R E SU LTS

| Global characteristics
The end result of the search was 13 unique observational studies 
| Procedure outcomes
The pooled adjusted device success rate was 95.0% (95% CI 90.2% to 98.5%). Significant, i.e., moderate or severe PVL was present in 12.2% (95% CI 3.1% to 24.7%), with the incidence varying markedly between studies ( Figure 2 ). Adjusted pooled major complication rates, including annular rupture and valve malposition, were extremely low ( Table 2 ).
| Safety outcomes
At 30-day adjudication, an early safety event had occurred in 16.9%
(95% CI 12.2% to 22.0%). The pooled adjusted all-cause mortality was 3.69% (95% CI 2.1% to 5.5%). The new PPM implantation rate was 17.9% (95% CI 14.1% to 21.9%) without significant heterogeneity between studies ( Figure 3 ). The rates of cardiac death, life threatening bleeding and major vascular complications were low (Table 3) . registry [29] . Outcomes in both our analysis and the TVT registry were site reported. The STS PROM was lower in the BcAV cohort (5.0% vs. 7.0%, P 5 0.04). This interesting finding may reflect a lower comorbidity burden in the relatively younger patients with bicuspid valve disease. However, it should be noted that STS PROM does not completely capture surgical risk, leaving out important determinants such as thoracic radiation and porcelain aorta, for example. We further note that the case series of TAVR for BcAV were performed in Europe and Canada, where there is no mandate for STS PROM based patient selection. The rate of all cause death at 30 days was lower in the BcAV cohort (3.7% vs. 7.6%, P < 0.01), which may reflect a lower overall procedural risk profile in these patients. Significant paravalvular leak (12.2% vs. 8.5%, P < 0.01) and new permanent pacemaker implantation (17.9% vs. 6.6%, P < 0.01) were both markedly higher in the BcAV cohort ( Figure 4 ). Both of these are known to be associated with increased long term morbidity and mortality despite otherwise successful TAVR in the TCAV population [33] . The prognostic implications for BcAV have not been studied but may be similar.
| Relevant comparisons
When compared to data from the ACC STS TVT Registry, which contains TCAV patients who received predominantly first generation devices (Sapien XT and CoreValve), we note that the PVL rate for BcAV patients is higher (12.2% vs. 8.5%), but not as marked when compared to the Sapien S3 and Evolut R data (3.4% and 3.4%). However, the differences in PPM rates go the other way, with the difference between extremely marked between the BcAV patients and the TVT registry (18% vs. 6.6%) and less so when compared to the Sapien S3 and Evolut R data (13.3% and 11.7%).
The mechanisms underlying increased PVL and PPM rates after TAVR in BcAV remain undefined. Previous hypotheses have invoked the presence of elliptical annuli, asymmetric cusps and focal calcifica-
tion. An elliptic annulus would not be expected to conform to a circular prosthesis. Asymmetric cusps can cause increased rates of valve malposition and focal calcification can foil attempts to fuse the valve skirt with the annulus, thereby producing PVL. In our analysis, the mean ellipticity index was 1.24. This corroborates prior data suggesting that
BcAV are not more elliptical than TCAV, thereby disproving prior hypotheses. We do not believe that this is a mechanism for the increased PVL seen in BcAV [34] . 
| C ONC LUSI ON S
Analysis of short term outcome data indicates that TAVR for patients with stenotic BcAV is associated with high rates of device success and low rates of early safety events. Mortality at 30 days is low and comparable to that achieved with the current generation of TAVR valves in stenotic TCAV. However, there remains a trend toward higher rates of significant PVL and PPM requirement. Newer iterations of transcatheter valves may improve outcomes for TAVR in BcAV, but it is possible that reduction in PVL might be accomplished at the expense of increased PPM implantion.
